Tokai Pharmaceuticals Inc. (TKAI) Shares Down 3.3%
Tokai Pharmaceuticals Inc. (NASDAQ:TKAI)’s share price was down 3.3% during mid-day trading on Friday . The company traded as low as $5.14 and last traded at $5.29, with a volume of 58,207 shares traded. The stock had previously closed at $5.47.
A number of brokerages have recently weighed in on TKAI. Janney Montgomery Scott began coverage on Tokai Pharmaceuticals in a report on Wednesday, April 6th. They set a “buy” rating on the stock. Bank of America Corp. began coverage on Tokai Pharmaceuticals in a report on Wednesday, April 6th. They set a “buy” rating and a $16.00 price target on the stock. Finally, BMO Capital Markets began coverage on Tokai Pharmaceuticals in a report on Monday, April 11th. They set an “outperform” rating and a $11.00 price target on the stock. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $18.00.
The stock’s market cap is $117.77 million. The company’s 50-day moving average price is $5.81 and its 200 day moving average price is $6.32.
Tokai Pharmaceuticals (NASDAQ:TKAI) last posted its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.01. Analysts forecast that Tokai Pharmaceuticals Inc. will post ($2.00) EPS for the current fiscal year.
Tokai Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Company’s lead drug candidate, galeterone, is an oral small molecule that utilizes the mechanistic pathways of second-generation androgen signaling inhibitors, while also introducing a third mechanism-androgen receptor degradation.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.